

4.0.3 DOC Cmte minutes

Parkinson's disease guideline committee meeting

Date: 08/06/2015

Location: London - Southbank , Elephant and Castle - Avonmouth House, 6
Avonmouth Street, SE1 6NX

Minutes: Final

Committee members present:		
Paul Cooper (Chair)		Present for notes 1-9
Alistair Church (AC)		Present for notes 1-9
Fiona Lindop (FL)		Present for notes 1-9
Graham Lennox (GL)		Present for notes 1-9
Ivan Bennett (IB)		Present for notes 1-9
Jane Little (JL)		Present for notes 1-9
Janine Barnes (JB)		Present for notes 1-9
Matthew Sullivan (MS)		Present for notes 1-9
Richard Grunewald (RG)		Present for notes 1-9
Debbie Davies (DD)		Present for notes 1-9
Paul Shotbolt (PS)		Present for notes 1-9
Richard Walker (RW)		Present for notes 1-9
Lynne Osborne (LO)		Present for notes 1-9
Robin Fackrell (RF)		Present for notes 1-9

In attendance:		
Gabriel Rogers	Technical Adviser	Present for notes 1-9
Louise Shires	Guideline Commissioning Manager	Present for notes 1-7

4.0.3 DOC Cmte minutes

Laura Downey	Technical Analyst	Present for notes 1-9
Stephanie Mills	Project Manager	Present for notes 1-9
Steven Ward	Health Economist	Present for notes 1-9

Observers:

N/A

Apologies:

N/A

1, 2 and 3 Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the fifth meeting on Parkinson's disease. The Committee members and attendees introduced themselves.

No further conflicts of interest above what had been made known to the NICE team were declared by any other person present.

The committee looked over the minutes of the previous meeting and agreed they were an accurate representation of the meeting in April 2015.

The Chair outlined the objectives of the meeting, which included look at the evidence on potential predictors for the development of impulse control behaviours as an adverse effect of dopaminergic treatment and the management of impulse control disorder.

4. Presentations : Review question 8:

The Chair introduced Laura Downey, Technical Analyst, who gave a presentation on *'What factors should healthcare professionals consider as potential predictors of impulse control behaviours as an adverse effect of dopaminergic treatment?'*

The Committee then discussed the evidence presented in relation to this question. The group debated what a clinically significant increase in risk may be. How the evidence matched with experience in clinical practice was also discussed by the committee. They then went on to make recommendations.

5. Presentations: Review question 9

Following lunch, Laura Downey gave a presentation on *'How should dopaminergic treatment be managed in people who have developed impulse control disorder as an*

4.0.3 DOC Cmte minutes

adverse effect?'

The committee discussed the interventions which emerged in the literature and how this would work in clinical practice among other issues. They then went on to make recommendations.

6. Health economics modelling update

The Chair introduced Steven Ward, Health Economist on the Internal Clinical Guidelines technical team. The Committee were re-presented with the ideas underpinning the plan for health economic modelling to underpin the clinical reviews on deep brain stimulation, duodopa and best medical therapy. The group confirmed they want this to be the focus of the guideline de novo modelling work.

Steven went on to explain a possible structure for the model, asking the committee for their thoughts on this and what potential sources of model inputs could be used.

7. Linking evidence to recommendations tables

The Committee were asked to look at the draft summary of their discussions from earlier in the day, relating to how they had formulated their recommendations.

The committee made a few minor changes. Laura agreed to complete writing the linking evidence to recommendations in full prose to be sent out to the committee in the week following the meeting.

8. Ratifying review protocols

The committee were asked to discuss and agree the appropriate criteria to populate the review protocol for '*What is the comparative effectiveness of second generation antipsychotics for psychotic symptoms associated with PD?*'

9. Summary and next steps

Stephanie Mills, the guideline Project Manager, thanked the group for their attendance and confirmed the date and location of the next meeting.

Date of next meeting: 20/07/2015

Location of next meeting: NICE Offices, Manchester